Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Secretary Azar Likely To Advance Medicare Drug Pricing Policies

Executive Summary

Alex Azar's nomination clears Senate with support from five Democrats and one Independent – but not Rand Paul, R-Ky.

You may also be interested in...



The Ups and Downs Of US Drug Pricing Policy

If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.

Groundhog Day For HHS And Drug Pricing? Why It Might Be Different This Time

President Trump has directed his new HHS Secretary to bring down drug prices – starting 2018 exactly the same way as 2017. But this time it could end differently.

Trump Emphasizes Foreign Drug Prices At Alex Azar's Swearing In

HHS secretary will get US drug prices 'way down … because it’s very unfair to our country,' president says. Also, 'we’re going to be very tough' on drug companies in combating the opioid crisis, Trump says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel